Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18011053 | 0.89 | AAK1 (0.80) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL16646766 | 0.87 | AAK1 (1.00) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL16646791 | 0.86 | AAK1 (0.75) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL1220119 | 0.83 | AAK1 (0.80) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL16646861 | 0.81 | AAK1 (0.69) | AAK1 | |
| SCHEMBL14017663 | 0.81 | AAK1 (0.74) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL16646843 | 0.80 | AAK1 (0.73) | AAK1EGFRERBB2LCK | |
| SCHEMBL4322112 | 0.79 | AAK1 (0.66) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL1220113 | 0.79 | AAK1 (0.66) | AAK1EGFRERBB2LCKKDR | |
| SCHEMBL4341416 | 0.79 | AAK1 (0.66) | AAK1EGFRERBB2LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | AAK1, DAPK2, DAPK1 | AAK1 1/4885GPR119 3660/4885EGFR 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.